• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

What to Know About the Latest Advances in Managing Severe Asthma
Graphs and charts don’t always tell the whole story. Numbers can be deceiving. But anyone who looks at U.S. trends in asthma mortality can see, without squinting, that things are moving in the right direction. A 2019 analysis in the American Journal of Respiratory and Critical Care Medicine found that from 1999 to 2015, asthma mortality fell by 43%. “The decrease in asthma-related mortality was consistent in both sexes and in all race groups, with the largest decrease in patients older than 65 years,” the authors concluded. Figures from the U.S. Centers for Disease Control and Prevention indicate that the...
Source: TIME: Health - June 23, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news

Biologicals In Severe asthma – Stopping The Unstoppable
Various society guidelines recommend biologicals (Anti IgE Omalizumab or anti IL5 – Mepolizumab) as an add on therapy for management of severe asthma, but there is no consensus on stoppage of these drugs after obtaining good asthma control. COVID 19 pandemic with lockdowns led to unintentional& unavoidable interruption in administering these drugs and paved way for us to analyze the effects of stoppage of these biologicals in severe asthmatics well controlled on these drugs.
Source: Journal of Allergy and Clinical Immunology - February 1, 2022 Category: Allergy & Immunology Authors: Manu Chopra, Meenakshi Chopra, Indramani Pandey, Vasu Vardhan, Rajan Kapoor, BNBM Prasad Source Type: research

Severe asthma biologic treatment in the era of COVID-19 - case series
Conclusions: Only a minority of this population tested positive for COVID-19 and none of them developed serious disease, supporting the evidence that both severe type-2 asthma and its targeted treatment do not convey increased risk for disease. However, additional studies regarding long-term complications should also be performed.
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Costa, P. M. N., Loureiro, C. C. Tags: Allergy and immunology Source Type: research

The course of COVID-19 in patients with severe asthma receiving biological treatment
Conclusion: Severe asthma itself seems to be a risk factor for COVID-19, whether biological treatment has a role in the disease course needs further research.PMID:34669544 | DOI:10.1080/02770903.2021.1996599
Source: Journal of Asthma - October 20, 2021 Category: Respiratory Medicine Authors: G ülseren Tuncay Mehmet Erdem Cakmak Ozge Can Bostan Saltuk Bugra Kaya Ebru Damadoglu G ül Karakaya Ali Fuat Kalyoncu Source Type: research

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news